MA43828A - Agents thérapeutiques pour maladies neurodégénératives - Google Patents
Agents thérapeutiques pour maladies neurodégénérativesInfo
- Publication number
- MA43828A MA43828A MA043828A MA43828A MA43828A MA 43828 A MA43828 A MA 43828A MA 043828 A MA043828 A MA 043828A MA 43828 A MA43828 A MA 43828A MA 43828 A MA43828 A MA 43828A
- Authority
- MA
- Morocco
- Prior art keywords
- neurodegenerative diseases
- therapeutic agents
- leucine
- acetyl
- administration
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 abstract 1
- 229960000669 acetylleucine Drugs 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Transplantation (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne le traitement de maladies neurodégénératives comprenant l'administration d'acétyl-leucine ou d'un sel pharmaceutiquement acceptable de celle-ci.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1613829.9A GB201613829D0 (en) | 2016-08-11 | 2016-08-11 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| GBGB1702551.1A GB201702551D0 (en) | 2017-02-16 | 2017-02-16 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| GBGB1705766.2A GB201705766D0 (en) | 2017-04-10 | 2017-04-10 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| GBGB1706867.7A GB201706867D0 (en) | 2017-04-28 | 2017-04-28 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| PCT/IB2017/054929 WO2018029658A1 (fr) | 2016-08-11 | 2017-08-11 | Agents thérapeutiques pour maladies neurodégénératives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA43828A true MA43828A (fr) | 2018-12-26 |
| MA43828B1 MA43828B1 (fr) | 2019-09-30 |
Family
ID=59859424
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047521A MA47521A (fr) | 2016-08-11 | 2017-08-11 | Agents thérapeutiques pour maladies neurodégénératives |
| MA43828A MA43828B1 (fr) | 2016-08-11 | 2017-08-11 | Agents thérapeutiques pour maladies neurodégénératives |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047521A MA47521A (fr) | 2016-08-11 | 2017-08-11 | Agents thérapeutiques pour maladies neurodégénératives |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US12144792B2 (fr) |
| EP (3) | EP3583940A1 (fr) |
| JP (3) | JP6957602B2 (fr) |
| KR (4) | KR20220093385A (fr) |
| CN (4) | CN116492328A (fr) |
| AU (3) | AU2017308865B2 (fr) |
| BR (1) | BR112019002730A2 (fr) |
| CA (1) | CA3033564A1 (fr) |
| CY (1) | CY1121930T1 (fr) |
| DK (1) | DK3416631T3 (fr) |
| ES (1) | ES2733677T3 (fr) |
| HR (1) | HRP20191055T1 (fr) |
| HU (1) | HUE045043T2 (fr) |
| IL (3) | IL310799A (fr) |
| LT (1) | LT3416631T (fr) |
| MA (2) | MA47521A (fr) |
| MD (1) | MD3416631T2 (fr) |
| ME (1) | ME03454B (fr) |
| MX (3) | MX383499B (fr) |
| PL (1) | PL3416631T3 (fr) |
| PT (1) | PT3416631T (fr) |
| RS (1) | RS59048B1 (fr) |
| RU (1) | RU2756519C2 (fr) |
| SG (1) | SG11201901063SA (fr) |
| SI (1) | SI3416631T1 (fr) |
| SM (1) | SMT201900370T1 (fr) |
| TN (1) | TN2019000033A1 (fr) |
| WO (1) | WO2018029658A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10219815B2 (en) | 2005-09-22 | 2019-03-05 | The Regents Of The University Of Michigan | Histotripsy for thrombolysis |
| JP6979882B2 (ja) | 2015-06-24 | 2021-12-15 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | 脳組織の治療のための組織破砕療法システムおよび方法 |
| HUE052837T2 (hu) | 2016-08-11 | 2021-05-28 | Intrabio Ltd | Lizoszóma-tárolási betegségre irányuló gyógyászati készítmények és alkalmazásaik |
| BR112019002730A2 (pt) | 2016-08-11 | 2019-05-14 | Intrabio Ltd | acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| SMT202500483T1 (it) * | 2017-10-18 | 2026-01-12 | Intrabio Ltd | Agenti terapeutici da utilizzare nel trattamento della sindrome delle gambe senza riposo |
| SI3752141T1 (sl) * | 2018-02-15 | 2024-09-30 | Intrabio Ltd. | Acetil-levcin za uporabo pri zdravljenju sindroma nemirnih nog |
| CN113286552B (zh) | 2018-11-28 | 2025-05-02 | 希斯托索尼克斯公司 | 组织摧毁术系统及方法 |
| KR20250022899A (ko) * | 2018-12-06 | 2025-02-17 | 인트라바이오 리미티드 | 아세틸-류신의 중수소화된 유사체 |
| SG11202109512SA (en) * | 2019-03-02 | 2021-09-29 | Intrabio Ltd | Leucine, acetyl leucine, and related analogs for treating disease |
| WO2021055443A1 (fr) * | 2019-09-17 | 2021-03-25 | Hoffmann-La Roche Inc. | Améliorations apportées à des soins de santé personnalisés destinés à des patients atteints de troubles de la motricité |
| WO2021144720A1 (fr) * | 2020-01-13 | 2021-07-22 | Intrabio Ltd | Traitement de maladies neurodégénératives tardives chez des porteurs de mutations hétérozygotes du gène npc1 |
| CA3179105A1 (fr) * | 2020-05-22 | 2021-11-25 | Michael Strupp | Association d'acetylleucine et de 4-aminopyridine ou d'acetazolamide pour traiter l'ataxie |
| WO2022264037A1 (fr) * | 2021-06-14 | 2022-12-22 | Intrabio Ltd. | Dérivés d'acides aminés à chaîne ramifiée pour traiter une maladie |
| US20240149078A1 (en) | 2022-10-28 | 2024-05-09 | Histosonics, Inc. | Histotripsy systems and methods |
| KR20260003742A (ko) | 2023-04-20 | 2026-01-07 | 히스토소닉스, 인크. | 치료 계획 및 요법을 위한 사용자 인터페이스들 및 작업 흐름들을 포함하는 히스토트립시 시스템들 및 연관된 방법들 |
| WO2025151578A1 (fr) * | 2024-01-12 | 2025-07-17 | Intrabio Inc. | N-acétyl-leucine destinée à être utilisée dans le traitement d'alpha-synucléinopathies prodromales |
| WO2025163129A1 (fr) * | 2024-02-01 | 2025-08-07 | Intrabio Ltd. | Acétylleucine pour le traitement de la maladie de parkinson |
| US12403111B2 (en) | 2024-02-02 | 2025-09-02 | SynGAP Research Fund | Compositions and methods for treating neurodevelopmental disorders |
| WO2025175092A1 (fr) * | 2024-02-14 | 2025-08-21 | Intrabio Inc. | Acétylleucine pour le traitement de troubles liés à syngap1 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| US20050222209A1 (en) * | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| FR2905600B1 (fr) | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| WO2008101693A2 (fr) | 2007-02-22 | 2008-08-28 | Beiersdorf Ag | Applications cosmétiques et pharmaceutiques d'acides aminés n-acylés, et composés structurellement apparentés |
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| TN2010000566A1 (en) * | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| EP3062810A4 (fr) * | 2013-10-28 | 2017-05-03 | Naurex Inc. | Modulateurs du récepteur nmda et promédicaments, sels et utilisations de ces derniers |
| HUE069219T2 (hu) | 2016-04-19 | 2025-02-28 | Intrabio Ltd | Acetil-leucin vagy gyógyszerészetileg elfogadható sója javított mozgásképességért |
| BR112019002730A2 (pt) | 2016-08-11 | 2019-05-14 | Intrabio Ltd | acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa |
-
2017
- 2017-08-11 BR BR112019002730-0A patent/BR112019002730A2/pt not_active Application Discontinuation
- 2017-08-11 PL PL17767934T patent/PL3416631T3/pl unknown
- 2017-08-11 CN CN202310629563.6A patent/CN116492328A/zh active Pending
- 2017-08-11 WO PCT/IB2017/054929 patent/WO2018029658A1/fr not_active Ceased
- 2017-08-11 LT LTEP17767934.7T patent/LT3416631T/lt unknown
- 2017-08-11 CA CA3033564A patent/CA3033564A1/fr active Pending
- 2017-08-11 SG SG11201901063SA patent/SG11201901063SA/en unknown
- 2017-08-11 EP EP19174007.5A patent/EP3583940A1/fr active Pending
- 2017-08-11 KR KR1020227021012A patent/KR20220093385A/ko not_active Ceased
- 2017-08-11 US US16/324,353 patent/US12144792B2/en active Active
- 2017-08-11 CN CN202310627214.0A patent/CN116459244A/zh active Pending
- 2017-08-11 TN TNP/2019/000033A patent/TN2019000033A1/fr unknown
- 2017-08-11 ME MEP-2019-169A patent/ME03454B/fr unknown
- 2017-08-11 KR KR1020197007032A patent/KR102413756B1/ko active Active
- 2017-08-11 KR KR1020247014635A patent/KR102785448B1/ko active Active
- 2017-08-11 HR HRP20191055TT patent/HRP20191055T1/hr unknown
- 2017-08-11 SM SM20190370T patent/SMT201900370T1/it unknown
- 2017-08-11 KR KR1020257008819A patent/KR20250042197A/ko active Pending
- 2017-08-11 EP EP17767934.7A patent/EP3416631B1/fr active Active
- 2017-08-11 HU HUE17767934A patent/HUE045043T2/hu unknown
- 2017-08-11 AU AU2017308865A patent/AU2017308865B2/en active Active
- 2017-08-11 RU RU2019106506A patent/RU2756519C2/ru active
- 2017-08-11 RS RS20190801A patent/RS59048B1/sr unknown
- 2017-08-11 MA MA047521A patent/MA47521A/fr unknown
- 2017-08-11 DK DK17767934.7T patent/DK3416631T3/da active
- 2017-08-11 IL IL310799A patent/IL310799A/en unknown
- 2017-08-11 CN CN202511449973.8A patent/CN121081445A/zh active Pending
- 2017-08-11 SI SI201730071T patent/SI3416631T1/sl unknown
- 2017-08-11 IL IL310801A patent/IL310801A/en unknown
- 2017-08-11 EP EP24191483.7A patent/EP4467195A3/fr active Pending
- 2017-08-11 JP JP2019507819A patent/JP6957602B2/ja active Active
- 2017-08-11 CN CN201780059708.6A patent/CN109789114A/zh active Pending
- 2017-08-11 IL IL264641A patent/IL264641B2/en unknown
- 2017-08-11 PT PT17767934T patent/PT3416631T/pt unknown
- 2017-08-11 ES ES17767934T patent/ES2733677T3/es active Active
- 2017-08-11 MD MDE20190027T patent/MD3416631T2/ro unknown
- 2017-08-11 MA MA43828A patent/MA43828B1/fr unknown
- 2017-08-11 MX MX2019001575A patent/MX383499B/es unknown
-
2019
- 2019-02-07 MX MX2021006901A patent/MX2021006901A/es unknown
- 2019-07-16 CY CY20191100759T patent/CY1121930T1/el unknown
-
2021
- 2021-10-06 JP JP2021164793A patent/JP7833272B2/ja active Active
-
2023
- 2023-03-15 US US18/183,972 patent/US20230210799A1/en active Pending
- 2023-04-05 AU AU2023202121A patent/AU2023202121B2/en active Active
- 2023-09-08 JP JP2023146465A patent/JP2023175762A/ja active Pending
-
2024
- 2024-01-12 US US18/411,512 patent/US20240189267A1/en active Pending
- 2024-04-11 MX MX2024004439A patent/MX2024004439A/es unknown
-
2025
- 2025-03-21 AU AU2025202077A patent/AU2025202077A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43828B1 (fr) | Agents thérapeutiques pour maladies neurodégénératives | |
| MA49664A (fr) | Combinaisons d'un dérivé de 4-pyrimidinesulfamide avec des principes actifs pour le traitement de maladies liées à l'endothéline | |
| EP3490987A4 (fr) | Nouveaux agents thérapeutiques pour le traitement de l'infection par hbv. | |
| MA49279A (fr) | Compositions d'anticorps optimisées pour le traitement de troubles oculaires | |
| MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
| EA202090510A1 (ru) | Способ лечения бокового амиотрофического склероза придопидином | |
| EP3612566A4 (fr) | Anticorps antagonistes de cd 14 pour le traitement de maladies neurodégénératives | |
| EP3829569A4 (fr) | Formulations de spinosyne pour le traitement de maladies oculaires et faciaux provoquées par demodex | |
| EP3934646A4 (fr) | Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires | |
| EP3607952A4 (fr) | Utilisation de carrimycine et d'un sel pharmaceutiquement acceptable de celle-ci pour la fabrication d'un médicament pour le traitement et/ou la prévention de tumeurs | |
| EP3481385C0 (fr) | Système d'administration de médicament pulsatile pour le traitement de l'akinésie matinale | |
| EP3773629A4 (fr) | Thérapies à base de car-treg pour le traitement de maladies neurodégénératives | |
| MA54077A (fr) | Polythérapie pour le traitement de maladies hématologiques | |
| EP3539550A4 (fr) | Composition pharmaceutique pour la prevention ou le traitement de maladies neurodegeneratives comprenant comme principe actif de l'extrait de fleur de daphné lilas ou des fractions de celui-ci | |
| MA51136A (fr) | Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc | |
| MA42301B1 (fr) | Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone | |
| EP3804739A4 (fr) | Composition comprenant un extrait d'aster sphathulifolius maxim pour la prévention, l'amélioration ou le traitement des maladies musculaires ou pour l'amélioration des fonctions musculaires | |
| MA43876B1 (fr) | Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale | |
| MA50383B1 (fr) | Agents thérapeutiques pour l'utilisation dans le traitement du syndrome des jambes sans repos | |
| MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| MA39837B1 (fr) | Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1 | |
| EP3530278A4 (fr) | Composition comprenant un peptide inhibiteur de protéine phosphatase 1 pour le traitement des maladies vasculaires | |
| MA44660B1 (fr) | (+) -azasetron pour son utilisation dans le traitement des troubles de l'oreille | |
| MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| MA46778A1 (fr) | Composition intranasale comprenant de la bétahistine |